Key result
MRAs cut clinical risk ~37% in high-aldosterone heart failure but worsen low-aldosterone cases.
Why the study?
MRAs increase aldosterone production and sub-saturating doses may allow continued MR stimulation, prompting analysis of how baseline and changes in aldosterone concentrations impact MR activity and clinical outcomes.
Does MRA use improve clinical outcomes and MR activity in heart failure patients depending on baseline aldosterone concentrations?
Meta-Analysis (n=1,772)
Yes
Does MRA use improve clinical outcomes and MR activity in heart failure patients depending on baseline aldosterone concentrations?
Hazard Ratio: 0.63 (95% CI 0.42–0.92)
p-value: p=0.02
The clinical benefit of MRAs in heart failure may depend on baseline aldosterone concentrations, with benefit observed in patients with high aldosterone but potential harm in those with low aldosterone.
No takes yet. Share an insight, caveat, or question.
Aldosterone measurement may guide MRA decisions in HF; leaves open randomized trials of stratified therapy.
Rao et al. (2026) conducted a meta-analysis in Heart failure (n=1,772). Mineralocorticoid receptor antagonists (MRAs) vs. No MRA was evaluated on Clinical outcomes (HR 0.63, 95% CI 0.42-0.92, p=0.02). In heart failure patients with high pre-MRA aldosterone, MRA use improved clinical outcomes (HR 0.63; 95% CI 0.42-0.92), but worsened outcomes in those with low pre-MRA aldosterone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: